Analyst Note
| Julie Utterback, CFA |Centene turned in stronger-than-expected first-quarter results, and management increased its outlook for 2022. Even when accounting for these strong trends, our $91 fair value estimate has not changed materially. We continue to see a narrow economic moat around Centene, which maintains strongholds in government-sponsored programs, like Medicaid, the individual exchanges, and Medicare Advantage.